Received May 9, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
her first dose she did have injection site pain; she had a lump; her arm was swollen; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site pain in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced injection site pain (Verbatim: her first dose she did have injection site pain), injection site lump (Verbatim: she had a lump) and swelling arm (Verbatim: her arm was swollen). The outcome of the injection site pain, injection site lump and swelling arm were unknown. It was unknown if the reporter considered the injection site pain, injection site lump and swelling arm to be related to Shingrix. It was unknown if the company considered the injection site pain, injection site lump and swelling arm to be related to Shingrix. Linked case(s) involving the same patient: US2026057289 Additional Information: GSK Receipt Date: 27-APR-2026 The first dose of Shingrix the patient stated her arm was swollen, she had a lump and injection site pain. The batch number was not provided upon follow- up with the reporter.